Personalis, Inc.’s Post

At #ASCO24 earlier this year, our collaborators presented impactful data highlighting NeXT Personal®, including two podium presentations! If you want to learn more about these data in breast cancer (in collaboration with The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust) and immunotherapy monitoring (in collaboration with Vall d'Hebron Institute of Oncology (VHIO)), check out our webinar with Endpoints News. In the breast cancer study with The Royal Marsden, NeXT Personal found that 100% of patients with undetectable residual disease in repeat testing did not have cancer recurrence. ctDNA detection correctly identified disease recurrence with a 15-month median lead time over imaging detection in all 14 patients that relapsed. Watch the recording to learn more about the data presented at ASCO: https://bit.ly/4aUaRD7. #PrecisionOncology #Liquidbiopsy #BreastCancer #ctDNA #ImmunoTherapy

We’re honored to have recently celebrated our 5-year listing anniversary on NASDAQ! We’ve continuously been a leader in advanced genomics for cancer, and have strived to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. #PrecisionOncology #Genomics #NGS

Take a look at this poster from #ASCO24 presented by Dr. Andrew Nixon from Duke Cancer Institute and Dr. Fábio C. P. Navarro from Personalis highlighting data in patients with late-stage esophagogastric cancer that received immunotherapy in combination with chemotherapy as part of the KeyLargo trial. Dr. Nixon found that ctDNA levels were demonstrated to be highly prognostic for therapy response. In late-stage cancer patients, ctDNA levels can be very low with ~20% of samples falling in the ultra-sensitive range, underscoring the importance of an ultra-sensitive test like NeXT Personal®. #ImmunoTherapy #PrecisionOncology #LiquidBiopsy #ctDNA

Compelling data presented at #ASCO24 by our collaborators at the Dana-Farber Cancer Institute from the DAPHNe trial. In a study of patients with early stage HER2+ breast cancer receiving neoadjuvant paclitaxel/trastuzumab/ pertuzumab (THP), 50 were sequenced with NeXT Personal®, which demonstrated 92% baseline detection (27% of detections were in the ultra-sensitive range below 100 PPM). NeXT Personal was also able to demonstrate neoadjuvant THP treatment effectiveness by showing the treatment had cleared the tumor MRD. #PrecisionOncology #ctDNA #ImmunoTherapy